Investigational drug · Phase 3
JNJ-87189401
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Castration-resistant Prostatic Neoplasms.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "JNJ-87189401"
First trial start
2025
Sep 2, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JNJ-87189401", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Castration-resistant Prostatic Neoplasms
Approved drugs for the same conditions: Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "JNJ-87189401" as an intervention, largest first.
- A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)Pivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07164443 · 1,203 participants (planned) · Start Sep 2, 2025 · Primary completion Aug 18, 2028
Drug: Pasritamig; Best Supportive Care (BSC) and 1 more · For: Metastatic Castration-resistant Prostatic Neoplasms
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 176 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06095089 · 355 participants (planned) · Start Nov 1, 2023 · Primary completion Jun 21, 2027
Drug: JNJ-78278343; JNJ-87189401 and 3 more · For: Prostatic Neoplasms
Sites: Aurora, Colorado; Atlanta, Georgia; Minneapolis, Minnesota · 22 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07082920 · 140 participants (planned) · Start Jul 7, 2025 · Primary completion Nov 30, 2027
Drug: JNJ-78278343; JNJ-95298177 and 1 more · For: Prostatic Neoplasms
Sites: Sarasota, Florida; New York, New York; Cleveland, Ohio · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metastatic Castration-resistant Prostatic Neoplasms
- PasritamigJNJ-78278343Phase 34 trials
Johnson & Johnson (Janssen) · Solid Tumor, Metastatic Castration-resistant Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.